Moteur de recherche d’entreprises européennes
Financement de l’UE (8 080 000 €) : Évaluations psychiatriques à l’aide de marqueurs stratifiés intermédiaires - Sofia réf. : 115916 Hor01/04/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Évaluations psychiatriques à l’aide de marqueurs stratifiés intermédiaires - Sofia réf. : 115916
The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family organizations, regulators, ECNP and EFPIA partners, this project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. This project will concentrate on Schizophrenia (SZ), Alzheimer’s disease (AD), and Major Depression (MD), as these disorders share part of their symptomatology, in particular social withdrawal and certain cognitive deficits, such as deficits in attention, working memory and sensory processing. By applying innovative technologies (e.g. EEG, cognitive tasks, (f)MRI, smartphone monitoring, and (epi-)genetics) to deep phenotype a clinical cohort of SZ and AD patients combined with a wider analysis of existing clinical data sets from major European and global disease cohorts that also include MD, we will define a set of quantifiable biological parameters best able to cluster and differentiate SZ, AD, and MD patients that do, or do not, exhibit social withdrawal. First, by mining large European SZ, AD and MD cohort datasets with already available social and cognitive proxy measures, and, second, by obtaining objective measures of social exploration levels (using a novel smartphone application), phenotypic relationships with social and cognitive measures will be further tested. For instance we might predict that socially withdrawn individuals may have lower cognitive functioning and poorer clinical course compared to those who are more socially engaged.
| ACADEMISCH ZIEKENHUIS LEIDEN | 334 775 € |
| Alma Mater Studiorum - Universita Di Bologna | 100 000 € |
| Biotrial | 350 000 € |
| BOEHRINGER INGELHEIM INTERNATIONALGESELLSCHAFT mbH | 0,00 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 315 000 € |
| Consorcio Centro de Investigacion Biomedica en Red M.P | 678 450 € |
| DRUG TARGET ID B.V. | 200 250 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 100 000 € |
| Europese Federatie Van Familieverenigingen Van Psychiatrisch Zieke Personen Ivzw | 18 563,00 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| NOVARTIS PHARMA AG | 0,00 € |
| P1Vital Ltd. | 1 226 586 € |
| P1Vital Products Ltd. | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| RIJKSUNIVERSITEIT GRONINGEN | 2 105 481 € |
| Sbgneuro Ltd. | 490 500 € |
| STICHTING AMSTERDAM UMC | 775 000 € |
| STICHTING BURO ECNP | 168 500 € |
| STICHTING RADBOUD UNIVERSITEIT | 840 250 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
| The University of Exeter | 90 000 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 286 645 € |
https://cordis.europa.eu/project/id/115916
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ACADEMISCH ZIEKENHUIS LEIDEN - Financement de l’UE (8 080 000 €) : Évaluations psychiatriques à l’aide de marqueurs stratifiés intermédiaires - Sofia réf. : 115916"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
